New Delhi, Jan. 20 -- UK-based GSK Plc, on Tuesday, 20 January 2026, announced that the firm has signed a definitive agreement to potentially acquire the US-based biopharmaceutical company RAPT Therapeutics via a deal comprising an equity value of $2.2 billion, according to the official announcement.

The filing showed that the British biopharma company's acquisition moves come at a time when RAPT Therapeutics is focused on developing novel therapies for patients living with inflammatory and immunologic diseases.

"GSK Plc today announced that it has entered a definitive agreement to acquire RAPT Therapeutics, a California-based, clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients living with infl...